Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys (Q45401922)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys	scientific article

Statements

scholarly article

1 reference

14 December 2017

Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys (English)

1 reference

14 December 2017

vector-borne disease

0 references

1 reference

based on heuristic

inferred from title

Hiroyuki Mizuguchi

5

object named as

Hiroyuki Mizuguchi

1 reference

14 December 2017

7

object named as

Naoki Yamamoto

1 reference

14 December 2017

author name string

Kenji Someya

1

1 reference

14 December 2017

Ke-Qin Xin

2

1 reference

14 December 2017

Yasushi Ami

3

1 reference

14 December 2017

Yasuyuki Izumi

4

1 reference

14 December 2017

Shinrai Ohta

6

1 reference

14 December 2017

Mitsuo Honda

8

1 reference

14 December 2017

Kenji Okuda

9

1 reference

14 December 2017

language of work or name

0 references

publication date

12 July 2007

1 reference

14 December 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

14 December 2017

367

1 reference

14 December 2017

390-397

1 reference

14 December 2017

2

1 reference

14 December 2017

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

CD46 is a cellular receptor for group B adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Adenovirus vectors as recombinant viral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Prospects for vaccine protection against HIV-1 infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Defining the Protective Antibody Response for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.06.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2007.06.012

1 reference

14 December 2017

release_b7kibshbrzgahhrdutombdogcq

1 reference

https://api.fatcat.wiki/v0/release/b7kibshbrzgahhrdutombdogcq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45401922&oldid=2076624226"